Old Mutual Global Investors UK Ltd. boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 30.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 970,846 shares of the biotechnology company’s stock after buying an additional 225,953 shares during the quarter. United Therapeutics Corporation makes up 1.2% of Old Mutual Global Investors UK Ltd.’s investment portfolio, making the stock its 26th largest holding. Old Mutual Global Investors UK Ltd. owned 2.23% of United Therapeutics Corporation worth $113,773,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Empirical Finance LLC raised its position in United Therapeutics Corporation by 8.3% in the 3rd quarter. Empirical Finance LLC now owns 15,606 shares of the biotechnology company’s stock valued at $1,829,000 after buying an additional 1,190 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in United Therapeutics Corporation by 1.6% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 77,438 shares of the biotechnology company’s stock valued at $9,075,000 after buying an additional 1,226 shares during the last quarter. Wedge Capital Management L L P NC grew its stake in United Therapeutics Corporation by 21.8% in the 3rd quarter. Wedge Capital Management L L P NC now owns 11,488 shares of the biotechnology company’s stock valued at $1,346,000 after purchasing an additional 2,059 shares during the period. Wedbush Securities Inc. bought a new position in United Therapeutics Corporation in the 3rd quarter valued at $435,000. Finally, Nine Chapters Capital Management LLC bought a new position in United Therapeutics Corporation in the 3rd quarter valued at $352,000.

ILLEGAL ACTIVITY WARNING: “Old Mutual Global Investors UK Ltd. Has $113.77 Million Position in United Therapeutics Corporation (UTHR)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/old-mutual-global-investors-uk-ltd-has-113-77-million-position-in-united-therapeutics-corporation-uthr/1682609.html.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,235 shares of the firm’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $131.95, for a total value of $162,958.25. Following the sale, the chief executive officer now owns 2,304 shares of the company’s stock, valued at approximately $304,012.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $134.48, for a total value of $77,998.40. Following the completion of the sale, the director now directly owns 3,295 shares in the company, valued at approximately $443,111.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,389 shares of company stock worth $2,287,452. Insiders own 7.80% of the company’s stock.

A number of brokerages have issued reports on UTHR. Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 3rd. Jefferies Group LLC restated a “sell” rating and issued a $105.00 price objective on shares of United Therapeutics Corporation in a research note on Friday, July 14th. TheStreet downgraded United Therapeutics Corporation from a “b-” rating to a “c” rating in a research note on Friday, September 29th. Cowen and Company restated a “hold” rating and issued a $129.00 price objective on shares of United Therapeutics Corporation in a research note on Friday, October 27th. Finally, HC Wainwright restated a “hold” rating and issued a $95.00 price objective on shares of United Therapeutics Corporation in a research note on Thursday, October 26th. Five investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $132.82.

Shares of United Therapeutics Corporation (NASDAQ UTHR) traded up $0.55 on Monday, reaching $121.50. The company had a trading volume of 29,697 shares, compared to its average volume of 419,454. The stock has a market cap of $5,226.38, a PE ratio of 10.67 and a beta of 1.38. United Therapeutics Corporation has a twelve month low of $112.01 and a twelve month high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.01 by $2.26. The business had revenue of $445.50 million for the quarter, compared to analysts’ expectations of $426.43 million. United Therapeutics Corporation had a return on equity of 26.24% and a net margin of 30.50%. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.23 EPS. equities analysts forecast that United Therapeutics Corporation will post 11.92 EPS for the current year.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.